Suggests research in TheNew England Journal of Medicine.

Certified from medwireNews with authorization from Springer Health care Ltd. All rights reserved. Neither of these parties endorse or suggest any commercial products, services, or equipment.. Adjuvant chemoradiotherapy boosts esophageal cancer tumor survival By Lynda Williams Chemoradiotherapy significantly improves the outcome of patients undergoing surgery for cancers of the esophagus or esophagogastric junction and is well tolerated, suggests research in TheNew England Journal of Medicine. The phase III trial results showed that sufferers with resectable tumors survived for a median of 49.4 months when given a neoadjuvant regimen typically 6.6 weeks before surgery compared with 24.0 months for surgery alone .The second group consisted of health-plan members who were matched to each PCR-positive child . Matched controls were the same sex and age group , of the same race or ethnic group , and attended the same medical clinic as the PCR-positive children and were people on the date of the PCR test in the PCR-positive kids . We retained all matched settings who received a 5th dosage of DTaP before their anchor date. We used the same exclusion criteria referred to above to both control groups and excluded kids as controls if they had previously examined positive for pertussis.